We are a vertically integrated radiopharmaceutical therapeutics (RPT) company focused on improving cancer patient survival by efficiently developing targeted innovative drugs that harness the power of radioisotopes.
Explore our pipeline programs
We have built a diverse portfolio of radiopharmaceutical drug candidates ranging from discovery to late-stage clinical programs. We advance programs into formal clinical development after conducting rigorous preclinical evaluation and early human imaging studies, leveraging our learnings to guide patient selection and clinical development path.
Understand our approach to radiopharmaceuticals
We are building on the century old experience of radiation therapy by harnessing the power of radioisotopes and delivering them intravenously in a targeted manner directly to solid tumors, including metastatic disease, to selectively kill cancer cells.
Understand our science
We have conducted over 500 in-vivo experiments using our systematic, data-driven approach to drug discovery and development to create a robust product pipeline.
Meet our team
Entrepreneurial and repeatedly successful team with a shared vision to build the leading radiopharmaceutical therapeutics company